Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)
Gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) poses a substantial clinical burden in China.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Precision medicine in gastric cancer
- Gastric cancer
- DESTINY‑Gastric05 Phase 3 Trial of ENHERTU Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
- Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
- Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers